Hypertension: Key Biomarkers of Injury and Prognosis

Kelly Arps; John W. McEvoy

doi:10.1016/B978-0-323-54835-9.00003-X

Hypertension: Key Biomarkers of Injury and Prognosis

Kelly Arps, John W. McEvoy

Medicine

Johns Hopkins Ciccarone Center for the Prevention of Heart Disease

Research output: Chapter in Book or Conference Publication/Proceeding › Chapter › peer-review

Abstract

Hypertension is a multifactorial condition with multisystem morbidity. There is a promising role for biomarkers, particularly multimarker panels, to predict incident hypertension. Blood-based markers may also be used to screen for subclinical target organ damage in asymptomatic hypertensive patients, which may help personalize treatment intensity. In newly diagnosed or treatment-resistant hypertensives, biomarkers have the potential to identify the dominant physiologic process to guide individualized allocation of the various antihypertensive drug therapies. This chapter will discuss the utility of biomarkers representing overactivation of renin-angiotensin-aldosterone signaling, products of cardiac stress, and inflammatory and oxidative cascades in each of the aforementioned roles.

Original language	English
Title of host publication	Biomarkers in Cardiovascular Disease
Publisher	Elsevier
Pages	21-40
Number of pages	20
ISBN (Electronic)	9780323548359
DOIs	https://doi.org/10.1016/B978-0-323-54835-9.00003-X
Publication status	Published - 1 Jan 2018

Keywords

Albuminuria
Biomarker panel
Crp
Incident hypertension
Renin-angiotensin-aldosterone system
Resistant hypertension
Target organ damage
Troponin

Access to Document

10.1016/B978-0-323-54835-9.00003-X

Cite this

@inbook{d0ab3dfbfc9a4247ac7ef5f8c9a83920,

title = "Hypertension: Key Biomarkers of Injury and Prognosis",

abstract = "Hypertension is a multifactorial condition with multisystem morbidity. There is a promising role for biomarkers, particularly multimarker panels, to predict incident hypertension. Blood-based markers may also be used to screen for subclinical target organ damage in asymptomatic hypertensive patients, which may help personalize treatment intensity. In newly diagnosed or treatment-resistant hypertensives, biomarkers have the potential to identify the dominant physiologic process to guide individualized allocation of the various antihypertensive drug therapies. This chapter will discuss the utility of biomarkers representing overactivation of renin-angiotensin-aldosterone signaling, products of cardiac stress, and inflammatory and oxidative cascades in each of the aforementioned roles.",

keywords = "Albuminuria, Biomarker panel, Crp, Incident hypertension, Renin-angiotensin-aldosterone system, Resistant hypertension, Target organ damage, Troponin",

author = "Kelly Arps and McEvoy, {John W.}",

year = "2018",

month = jan,

day = "1",

doi = "10.1016/B978-0-323-54835-9.00003-X",

language = "English",

pages = "21--40",

booktitle = "Biomarkers in Cardiovascular Disease",

publisher = "Elsevier",

}

TY - CHAP

T1 - Hypertension

T2 - Key Biomarkers of Injury and Prognosis

AU - Arps, Kelly

AU - McEvoy, John W.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Hypertension is a multifactorial condition with multisystem morbidity. There is a promising role for biomarkers, particularly multimarker panels, to predict incident hypertension. Blood-based markers may also be used to screen for subclinical target organ damage in asymptomatic hypertensive patients, which may help personalize treatment intensity. In newly diagnosed or treatment-resistant hypertensives, biomarkers have the potential to identify the dominant physiologic process to guide individualized allocation of the various antihypertensive drug therapies. This chapter will discuss the utility of biomarkers representing overactivation of renin-angiotensin-aldosterone signaling, products of cardiac stress, and inflammatory and oxidative cascades in each of the aforementioned roles.

AB - Hypertension is a multifactorial condition with multisystem morbidity. There is a promising role for biomarkers, particularly multimarker panels, to predict incident hypertension. Blood-based markers may also be used to screen for subclinical target organ damage in asymptomatic hypertensive patients, which may help personalize treatment intensity. In newly diagnosed or treatment-resistant hypertensives, biomarkers have the potential to identify the dominant physiologic process to guide individualized allocation of the various antihypertensive drug therapies. This chapter will discuss the utility of biomarkers representing overactivation of renin-angiotensin-aldosterone signaling, products of cardiac stress, and inflammatory and oxidative cascades in each of the aforementioned roles.

KW - Albuminuria

KW - Biomarker panel

KW - Crp

KW - Incident hypertension

KW - Renin-angiotensin-aldosterone system

KW - Resistant hypertension

KW - Target organ damage

KW - Troponin

UR - http://www.scopus.com/inward/record.url?scp=85123671562&partnerID=8YFLogxK

U2 - 10.1016/B978-0-323-54835-9.00003-X

DO - 10.1016/B978-0-323-54835-9.00003-X

M3 - Chapter

AN - SCOPUS:85123671562

SP - 21

EP - 40

BT - Biomarkers in Cardiovascular Disease

PB - Elsevier

ER -

Hypertension: Key Biomarkers of Injury and Prognosis

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this